<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04992052</url>
  </required_header>
  <id_info>
    <org_study_id>21-0044-NSUH</org_study_id>
    <nct_id>NCT04992052</nct_id>
  </id_info>
  <brief_title>Bone Wax Use for Hemostasis During Primary Unilateral Total Knee Arthroplasty</brief_title>
  <official_title>A Prospective, Randomized, Single-blinded Superiority Study to Evaluate Bone Wax Use for Hemostasis During Primary Unilateral Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether the application of bone wax to exposed&#xD;
      cancellous bone, after the cemented implants are in place, will provide superior hemostasis&#xD;
      in total knee arthroplasty (TKA) patients compared to patients who do not have the bone wax&#xD;
      applied. Hemostasis will be assessed by calculating blood loss using the Hb-balance formula.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total joint arthroplasty can result in significant blood loss. Postoperative anemia has been&#xD;
      associated with prolonged length of stay and increased hospital costs.1 Minimizing blood loss&#xD;
      has led to multiple blood conservation strategies in orthopaedic procedures.&#xD;
&#xD;
      Bone wax is a well-known topical hemostatic agent comprised of a mixture of beeswax,&#xD;
      paraffin, and isopropyl palmitate. This inexpensive agent works by sealing the bleeding site&#xD;
      and tamponades bleeding from the cancellous bone. Bone wax can be precisely applied evenly&#xD;
      and stops bone bleeding immediately upon application.2&#xD;
&#xD;
      The purpose of this study is to assess whether the application of bone wax to exposed&#xD;
      cancellous bone, after the cemented implants are in place, will provide superior hemostasis&#xD;
      in total knee arthroplasty (TKA) patients compared to patients who do not have the bone wax&#xD;
      applied. Hemostasis will be assessed by calculating blood loss using the Hb-balance formula.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm 1 Bone wax applied to the exposed cancellous surfaces of the bone (treatment group).&#xD;
Arm 2 No bone wax. This group will serve as the control arm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Blinding of the principal investigator and operating staff is not possible. However, all attempts will be made to keep this information from the hospital staff caring for the patients in the postoperative period. The patient and the postoperative hospital staff will be blinded to the treatment arm. The OR staff will be trained not to discuss this information with the patient. During the transition of care from the OR to the Post Anesthetic Care Unit (PACU) the treatment arm will not be included in the verbal patient report. The lack of this information is not required to effectively manage the patient in the postoperative period and will not affect patient care. Postoperatively medical care is managed by the hospitalist, medical doctors specializing in the care of hospitalized patients.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Loss</measure>
    <time_frame>Blood loss is measured in the morning prior to receiving anticoagulant treatment.</time_frame>
    <description>To determine if there is a change in blood volume loss between the two study arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee Society Scoring System</measure>
    <time_frame>Preoperatively and 8 weeks postoperatively</time_frame>
    <description>To determine if there is a change in patient functional outcomes, as measured by the Knee Society Scoring System, between the two study arms. The minimum and maximum score for this scale ranges from 0-100. A higher score means a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Total Knee Replacement</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will have bone wax applied to the exposed cancellous surfaces of the bone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm will serve as the control group. Bone wax will not be used in this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bone wax</intervention_name>
    <description>The surgeons will apply the bone wax to the exposed cancellous bone after the implant has been cemented in place in patients randomized to the treatment arm.</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients scheduled for primary unilateral total knee arthroplasty&#xD;
&#xD;
          2. Preoperative Hemoglobin &gt;11mg/dL&#xD;
&#xD;
          3. Preoperative platelet count of &gt;150,000&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients unable to take aspirin or apixaban for VTE prophylaxis&#xD;
&#xD;
          2. Allergy to any of the ingredients in bone wax (beeswax, paraffin, or isopropyl&#xD;
             palmitate)&#xD;
&#xD;
          3. Patients taking clopidogrel (Plavix), ticagrelor (Brilinta), or prasugrel (Effient) or&#xD;
             any other antiplatelet medication (except for aspirin 81 mg)&#xD;
&#xD;
          4. Patients unable to get IV Tranexamic Acid for any reason&#xD;
&#xD;
          5. Patients requiring anticoagulant treatment prior to surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Krauss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Syosset Hospital, Northwell Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy Dengler, RN</last_name>
    <phone>516-496-2637</phone>
    <email>ndengler@northwell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Syosset Hospital</name>
      <address>
        <city>Syosset</city>
        <state>New York</state>
        <zip>11791</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Dengler, RN</last_name>
      <phone>516-809-6550</phone>
      <email>ndengler@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Eugene S Krauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayal Segal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shin KH, Choe JH, Jang KM, Han SB. Use of bone wax reduces blood loss and transfusion rates after total knee arthroplasty. Knee. 2020 Oct;27(5):1411-1417. doi: 10.1016/j.knee.2020.07.074. Epub 2020 Aug 19.</citation>
    <PMID>33010755</PMID>
  </reference>
  <reference>
    <citation>Noble PC, Scuderi GR, Brekke AC, Sikorskii A, Benjamin JB, Lonner JH, Chadha P, Daylamani DA, Scott WN, Bourne RB. Development of a new Knee Society scoring system. Clin Orthop Relat Res. 2012 Jan;470(1):20-32. doi: 10.1007/s11999-011-2152-z.</citation>
    <PMID>22065240</PMID>
  </reference>
  <results_reference>
    <citation>Moo IH, Chen JYQ, Pagkaliwaga EH, Tan SW, Poon KB. Bone Wax Is Effective in Reducing Blood Loss After Total Knee Arthroplasty. J Arthroplasty. 2017 May;32(5):1483-1487. doi: 10.1016/j.arth.2016.12.028. Epub 2016 Dec 24.</citation>
    <PMID>28089184</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Eugene Krauss</investigator_full_name>
    <investigator_title>Director of Orthopaedics, Syosset Hospital, Northwell Health System</investigator_title>
  </responsible_party>
  <keyword>Knee arthroplasty</keyword>
  <keyword>Total knee replacement</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone wax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

